USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: VIROGENOMICS, INC.
Address: 12909 SW 68th Parkway
TIGARD, OR
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,333,835.00 6
SBIR Phase II $489,496.00 1
STTR Phase I $2,505,529.00 13
STTR Phase II $4,330,926.00 5

Award List:

TREATMENT OF HCMV IN TRANSPLANT VASCULAR SCELROSIS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: James B. Hicks
Award Amount: $96,845.00
Abstract:
DESCRIPTION (provided by applicant): Transplant Vascular Sclerosis (TVS) is an accelerated form of arteriosclerosis that is responsible for significant number of cases of chronic rejection in solid organ transplantation procedures. The incidence of TVS is approximately 15% of patients per year,… More

A METHOD FOR TREATING HCMV IN VASCULAR DISEASE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: James B. Hicks
Award Amount: $96,105.00
Abstract:
Cardiovascular disease remains the most common cause of death in the United States. While atherosclerosis accounts for the majority of these deaths, other vasculopathies such as restenosis after coronary angioplasty, and transplant vascular sclerosis (TVS), the hallmark lesion of… More

IMPROVED CELL CULTURE SYSTEMS FOR HEPATITIS C VIRUS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: James Hicks
Award Amount: $98,329.00
Abstract:
DESCRIPTION (provided by applicant): Hepatitis C virus is rapidly becoming one of the most important infectious health problems and is approaching epidemic status world wide. The CDC estimates that HCV may have already infected more that three million people in the US alone. Treatments for the… More

Development of a T cell specific multiple sclerosis drug

Award Year / Program / Phase: 2004 / STTR / Phase II
Agency: HHS
Research Institution: OREGON HEALTH & SCIENCE UNIVERSITY
Principal Investigator: Arthur A. Vandenbark
Award Amount: $720,140.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS). The lead compound in the current proposal is VG1000, a minimal recombinant TCR ligand (RTL) containing MHC class II (1(1 domains of… More

Osteopontin, a Novel Neuroprotectant in Brain Ischemia

Award Year / Program / Phase: 2005 / STTR / Phase II
Agency: HHS
Research Institution: OREGON HEALTH SCIENCES UNIVERSITY
Principal Investigator: Mary P. Stenzelpoore
Award Amount: $751,716.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): This is an STTR Phase II proposal to develop the application of a novel neuroprotectant in the treatment of stroke. As in our previous Phase I STTR, this Phase II STTR unites the Stenzel-Poore laboratory and Virogenomics, Inc., a Portland-based genomics and drug… More

HLA-DR4-derived RTLs for Treating Rheumatoid Arthritis

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: OREGON HEALTH & SCIENCE UNIVESITY
Principal Investigator: Jianya Huan
Award Amount: $100,548.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The specific goal of this Phase I STTR is to design, manufacture, characterize and evaluate a set of therapeutic agents that can control the pathogenic CD4+ T cells that mediate an inflammatory autoimmune disease, rheumatoid arthritis (RA). The approach presented… More

Genetically Defined Attenuated Living Vaccine for Francisella

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: OREGON HEALTH AND SCIENCE UNIVERSITY
Principal Investigator: Fred L. Heffron
Award Amount: $588,104.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Tularemia is the severe and sometimes fatal disease caused by infection with Francisella tularensis. These bacteria are some of the most virulent pathogens known, requiring inoculation or inhalation with as few as 10 or ganisms to cause disease. Infections can be… More

Development of Neuroprotective Stroke Thereapy

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $123,759.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The potential of treatment for stroke may be accomplished via acute intervention at the time of the acute stroke or by providing prophylactic neuroprotection to at risk populations. The at risk group includes: 1) co ronary artery bypass surgery patients (who… More

Immunotherapeutic Approaches to Cancer Treatment

Award Year / Program / Phase: 2008 / STTR / Phase I
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $123,614.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Immunotherapy as a treatment for cancer has been intensely investigated, but few studies have resulted in meaningful clinical responses. Many fundamental principals of tumor immunology have been clarified in recent year s with the recognition and description of… More

A Novel Approach to Stroke Treatment: Acid-Sensing Iion Channel Inhibitors

Award Year / Program / Phase: 2009 / STTR / Phase I
Agency: HHS
Research Institution: EMANUEL HOSPITAL AND HEALTH CENTER
Principal Investigator: Roger P. Simon
Award Amount: $118,342.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death and a leading cause of serious, long-term disability in the United States. Although in recent years enormous progress has been made towards defining the cellular and molecular responses of the brain to ischemia, our… More

SBIR Phase I:Electronic allergy diagnostics: Photo-immobilization as a general strategy for attaching structurally and compositionally diverse ligands onto a single support

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: NSF
Principal Investigator: Brian Clare, PhD
Award Amount: $179,992.00
Abstract:
This Small Business Innovation Research (SBIR) Phase 1 project aims to rapidly address the feasibility of using photochemical linkers to immobilize small molecules, synthetic peptides, purified proteins and crude natural extracts onto an electrochemical sensor array. This study is motivated by 1)… More

Development of a plant-grown subunit vaccine against respiratory syncytial virus

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Renee L. Shirley
Award Amount: $581,068.00
Abstract:
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV)-caused disease represents a significant health care burden worldwide. The RSV infects virtually all children throughout the world in both developed and developing countries. Re-infecti on is common because natural infection does… More

Novel RTL treatment to promote brain repair and cognitive recovery following meth

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Oregon Health And Science University
Principal Investigator: Jennifer M. Loftis – 503-220-8262
Award Amount: $173,244.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, andmotivation. Currently, there are no… More

A Novel Intervention Strategy for Stroke with RTL Therapy

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency: HHS
Research Institution: OREGON HEALTH AND SCIENCE UNIVERSITY
Principal Investigator: Halina Offner – 503-721-7893
Award Amount: $1,350,283.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This application is a Phase II STTR to further the study of a novel therapeutic intervention for ischemic stroke. Phase I investigated the mechanism of protection against ischemic stroke provided by the novel designertherapy, recombinant T cell receptor ligand… More

SBIR Phase II: Electronic Allergy Diagnostics: Photo-Immobilization as a General Strategy for Attaching Structurally and Compositionally Diverse Ligands onto a Single Support

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: NSF
Principal Investigator: Jeff S. King
Award Amount: $489,496.00
Abstract:
This Small Business Innovation Research (SBIR) Phase II project aims to create better diagnostic testing for drug, food, and environmental allergies. If successful, it would be transformative in the clinical diagnosis of allergy diseases by enabling rapid evaluation at the doctor?s office in a… More

Electrochemical diagnostics for rapid, multiplexed detection of RA biomarkers

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jeff King – 503-626-8354
Award Amount: $281,496.00
Abstract:
DESCRIPTION (provided by applicant): Virogenomics is currently developing a portable, electrochemical device for rapid disease diagnosis of multiple indications. The basis of our approach is a patent-pending electrochemical immunoassay performed on patterned electrode arrays, and we take advantage… More